3.5001
price down icon4.39%   -0.1607
after-market アフターアワーズ: 3.59 0.0899 +2.57%
loading
前日終値:
$3.6608
開ける:
$3.645
24時間の取引高:
11,617
Relative Volume:
0.30
時価総額:
$3.35M
収益:
$61,000
当期純損益:
$-5.46M
株価収益率:
-0.5352
EPS:
-6.54
ネットキャッシュフロー:
$-6.76M
1週間 パフォーマンス:
-0.85%
1か月 パフォーマンス:
+2.64%
6か月 パフォーマンス:
-30.42%
1年 パフォーマンス:
-48.90%
1日の値動き範囲:
Value
$3.5001
$3.79
1週間の範囲:
Value
$3.5001
$4.1481
52週間の値動き範囲:
Value
$3.03
$14.80

Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile

Name
名前
Titan Pharmaceuticals Inc De
Name
セクター
Healthcare (1188)
Name
電話
(650) 244-4990
Name
住所
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
職員
0
Name
Twitter
@titanpharma
Name
次回の収益日
2024-06-28
Name
最新のSEC提出書
Name
TTNP's Discussions on Twitter

TTNP を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
3.5001 3.35M 61,000 -5.46M -6.76M -6.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.56 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.78 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
550.00 33.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.95 30.15B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
220.54 25.69B 3.81B -644.79M -669.77M -6.24

Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2019-06-26 開始されました Maxim Group Buy
2017-11-10 ダウングレード ROTH Capital Buy → Neutral

Titan Pharmaceuticals Inc De (TTNP) 最新ニュース

pulisher
Apr 04, 2025

Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan

Apr 04, 2025
pulisher
Mar 31, 2025

NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan

Mar 31, 2025
pulisher
Mar 23, 2025

$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan

Mar 23, 2025
pulisher
Mar 21, 2025

Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post

Mar 21, 2025
pulisher
Mar 20, 2025

Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan

Mar 20, 2025
pulisher
Mar 19, 2025

Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan

Mar 19, 2025
pulisher
Mar 13, 2025

Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan

Mar 13, 2025
pulisher
Mar 12, 2025

NRx Pharmaceuticals Readies Major Financial Update: Full Year Results and Strategic Outlook Coming March 17 - Stock Titan

Mar 12, 2025
pulisher
Mar 11, 2025

Armata CEO Dr. Deborah Birx Takes Center Stage at Major Bacteriophage Summit - Stock Titan

Mar 11, 2025
pulisher
Mar 10, 2025

Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan

Mar 07, 2025
pulisher
Mar 06, 2025

Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Will Amphastar Reveal New Strategic Insights at Upcoming Barclays Healthcare Conference? - Stock Titan

Mar 05, 2025
pulisher
Mar 04, 2025

When Will Lexicon Pharmaceuticals Reveal Its 2024 Financial Performance? - Stock Titan

Mar 04, 2025
pulisher
Mar 03, 2025

Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

When Will ARS Pharmaceuticals Reveal Its 2024 Financial Performance? - Stock Titan

Mar 03, 2025
pulisher
Feb 28, 2025

Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan

Feb 28, 2025
pulisher
Feb 27, 2025

Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - Stock Titan

Feb 27, 2025
pulisher
Feb 26, 2025

Can CNS Pharmaceuticals' $14M War Chest Deliver on Its Promising Brain Cancer Treatment? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Will Universe Pharmaceuticals Survive Nasdaq's Latest Delisting Threat? - StockTitan

Feb 25, 2025
pulisher
Feb 25, 2025

Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - Stock Titan

Feb 25, 2025
pulisher
Feb 24, 2025

Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - Stock Titan

Feb 24, 2025
pulisher
Feb 21, 2025

Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - StockTitan

Feb 21, 2025
pulisher
Feb 20, 2025

Can This $430M Pharma Merger Create the Next Women's Health Giant? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

Can CNS Pharmaceuticals' Brain Cancer Breakthrough Change Treatment Landscape? CEO Presents Next Week - Stock Titan

Feb 20, 2025
pulisher
Feb 19, 2025

Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - Stock Titan

Feb 19, 2025
pulisher
Feb 18, 2025

Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - Stock Titan

Feb 18, 2025
pulisher
Feb 14, 2025

Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan

Feb 14, 2025
pulisher
Feb 13, 2025

Elite Pharma Q3 Results Reveal Sharp Profit Decline: Holiday Delays Impact Performance - StockTitan

Feb 13, 2025
pulisher
Feb 11, 2025

Conduit Pharma (CDT) Slashes Debt Load: Strategic $2.3M Debt Restructuring Unveiled - Stock Titan

Feb 11, 2025
pulisher
Feb 10, 2025

Elite Pharmaceuticals (ELTP) Earnings Preview: Q3 Performance & Strategic Roadmap Unveiling Feb 14 - StockTitan

Feb 10, 2025
pulisher
Feb 10, 2025

Opioid Use Disorders Market to Reach USD 8.8 Billion by - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Axsome Wins Major Victory: 15+ Years Market Protection for AUVELITY Secured in Patent Deal - Stock Titan

Feb 10, 2025
pulisher
Feb 07, 2025

Critical Safety Signal Emerges: Pliant's IPF Drug Trial Faces Unexpected DSMB Intervention - StockTitan

Feb 07, 2025
pulisher
Feb 07, 2025

Breakthrough NPC1 Treatment Data: 87% of Young Patients Show Recovery Signs in Cyclo Trial - StockTitan

Feb 07, 2025
pulisher
Feb 07, 2025

Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan

Feb 07, 2025
pulisher
Feb 06, 2025

TFF Pharmaceuticals to Exit Nasdaq: Complete Liquidation Plan Leaves Shareholders in Limbo - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

Major Biotech Conferences Alert: NRx Pharmaceuticals Sets Stage for Key Industry Updates - StockTitan

Feb 06, 2025
pulisher
Feb 05, 2025

Oncology & Obesity Pipeline Update: Terns Pharmaceuticals Takes Center Stage at Major Healthcare Conference - StockTitan

Feb 05, 2025
pulisher
Feb 04, 2025

Inside Apellis' Strategic Move: New Talent Secured with 7,805 RSU Compensation Package - StockTitan

Feb 04, 2025
pulisher
Feb 04, 2025

KalVista Pharmaceutical's Major Talent Push: 261,000 Stock Options Awarded in Strategic Growth Move - StockTitan

Feb 04, 2025
pulisher
Feb 04, 2025

Cumberland's DMD Heart Disease Drug Shows Breakthrough 5.4% LVEF Improvement in Phase 2 | CPIX Stock News - Stock Titan

Feb 04, 2025
pulisher
Feb 03, 2025

Nasdaq Delisting Drama: Universe Pharmaceuticals Given 7 Days to Save Its Listing - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

X4 Pharma's Latest Employee Stock Plan: Strategic Move to Attract Top Talent - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Mental Health Revolution: HOPE's $27M Backed Ketamine Clinic Network Takes Shape With BTIG Partnership - StockTitan

Feb 03, 2025
pulisher
Jan 30, 2025

Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan

Jan 30, 2025
pulisher
Jan 30, 2025

Alnylam's Crucial 2024 Financial Results Coming: Key Date for Biotech Investors - Stock Titan

Jan 30, 2025

Titan Pharmaceuticals Inc De (TTNP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$60.29
price down icon 0.48%
$68.09
price down icon 1.58%
$17.32
price down icon 0.23%
$31.03
price down icon 0.26%
$86.82
price down icon 1.40%
biotechnology ONC
$220.54
price down icon 7.53%
大文字化:     |  ボリューム (24 時間):